TY  - JOUR
AU  - Bonanad, Santiago
AU  - Núñez, Ramiro
AU  - Poveda, Jose Luis
AU  - Kurnik, Karin
AU  - Goldmann, Georg
AU  - Andreozzi, Valeska
AU  - Vandewalle, Björn
AU  - Santos, Sandra
PY  - 2021
DO  - 10.1007/s12325-021-01853-0
UR  - http://hdl.handle.net/10668/18343
T2  - Advances in therapy
AB  - Given the relatively small number of patients with haemophilia A, head-to-head comparisons between recombinant FVIII (rFVIII) products are difficult to conduct. This study compared the efficacy and consumption of rVIII-SingleChain (lonoctocog alfa,...
LA  - en
KW  - Annualized bleeding rate
KW  - Efmoroctocog alfa
KW  - FVIII consumption
KW  - Haemophilia A
KW  - Lonoctocog alfa
KW  - MAIC
KW  - Matching-adjusted indirect comparison
KW  - Octocog alfa
KW  - rVIII-SingleChain
KW  - Adolescent
KW  - Adult
KW  - Factor VIII
KW  - Hemophilia A
KW  - Hemorrhage
KW  - Humans
KW  - Immunotherapy, Adoptive
KW  - Propensity Score
KW  - Recombinant Proteins
TI  - Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
TY  - research article
VL  - 38
ER  -